IL2 and melanoma: They are: (1) Vaccination of patients (pts) with advanced prostate cancer, with a preparation of PAP-loaded autologous dendritic cells [5]; (2) Augmenting endogenous anti-melanoma immunity via anti-CTLA-4 mAb [6,7]; and (3) Enhancing ADCC in children with neuroblastoma (NBL) by combining an anti-GD2 mAb with NK activation (via IL2) and neutrophil/monocyte activation (via GM-CSF) [8].